Clinical

Latest News


Latest Videos



More News

1 KOL is featured in this series.

A key opinion leader examines how the introduction of biologic therapies revolutionized atopic dermatitis treatment, addressing strategies to manage patients' concerns about needles and injections.

1 KOL is featured in this series.

A key opinion leader in dermatology explains how the presence of type 2 inflammation informs their treatment decisions for atopic dermatitis and prurigo nodularis, while also detailing additional patient-specific factors such as age, comorbidities, and disease severity that influence their therapeutic approach.

1 KOL is featured in this series.

A dermatologist explores the underlying type 2 inflammatory pathway linking atopic dermatitis and prurigo nodularis, highlighting specific biomarkers that aid in identifying patients with type 2 inflammation-driven dermatologic conditions.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text